11.A. Workshop: Risk-benefit Assessment of Foods and Diets for a Sustainable Future

被引：0

|

作者：

Pires, Sara

Thomsen, Sofie Theresa

机构：

来源：

EUROPEAN JOURNAL OF PUBLIC HEALTH | 2023年 / 33卷

关键词：

D O I：

暂无

中图分类号：

R1 [预防医学、卫生学];

学科分类号：

1004 ; 120402 ;

摘要：

ckad160.69

引用

收藏

页数：1

相关论文

共 50 条

[41] RISK-BENEFIT ASSESSMENT OF ANESTHETIC AGENTS IN THE PUERPERIUM
KANTO, J
DRUG SAFETY, 1991, 6 (04) : 285 - 301
[42] Risk-benefit assessment of nimesulide urgently needed
Reactions Weekly, 2003, 934 (1) : 3 - 3
[43] A risk-benefit assessment of irinotecan in solid tumours
Siu, LL
Rowinsky, EK
DRUG SAFETY, 1998, 18 (06) : 395 - 417
[44] Carbapenems in serious infections - A risk-benefit assessment
Norrby, SR
DRUG SAFETY, 2000, 22 (03) : 191 - 194
[45] A Risk-Benefit Assessment of Pharmacological Therapies for Hirsutism
Enrico Carmina
Drug Safety, 2001, 24 : 267 - 276
[46] RISK-BENEFIT PROBLEMS IN FOOD SAFETY ASSESSMENT
FRANCIS, FJ
JOURNAL OF THE CANADIAN DIETETIC ASSOCIATION-REVUE DE L ASSOCIATION CANADIENNE DES DIETETISTES, 1979, 40 (04): : 274 - 279
[47] A risk-benefit assessment of HIV protease inhibitors
Moyle, GJ
Gazzard, BG
DRUG SAFETY, 1999, 20 (04) : 299 - 321
[48] A Risk-Benefit Assessment of Octreotide in the Treatment of Acromegaly
Aart Jan van der Lely
Wouter W. de Herder
Steven W. J. Lamberts
Drug Safety, 1997, 17 : 317 - 324
[49] A risk-benefit assessment of oxytocics in obstetric practice
Winkler, M
Rath, W
DRUG SAFETY, 1999, 20 (04) : 323 - 345
[50] A Risk-Benefit Assessment of HIV Protease Inhibitors
Graeme J. Moyle
Brian G. Gazzard
Drug Safety, 1999, 20 : 299 - 321

← 1 2 3 4 5 →